Kalaris Therapeutics, Inc. (KLRS) Stock Forecast & Price Target
Kalaris Therapeutics, Inc. · NASDAQ
$3.32-0.26 (-7.26%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Kalaris Therapeutics, Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $14.00 to $25.00, a moderate spread. The average target of $18.67 sits 462% above the current $3.32. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.52 next quarter toward $-1.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy117%
Buy583%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Kalaris Therapeutics, Inc.
As of Jul, 6 of 6 firms rate KLRS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
KLRS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.52
Range $-0.58 – $-0.39 · 8 analysts · -19% YoY
Next period, 8 analysts expect Kalaris Therapeutics, Inc. to earn $-0.52 a share (range $-0.58 – $-0.39), versus $-0.64 a year earlier. Full-year consensus is $-2.03, growing to $-1.63 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 8 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $11.4M next year.
Top analysts covering Kalaris Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KLRS.
#1
Daniil Gataulin
Chardan Capital · Rank #36
Buy
$19.00+472.3% to target
Overall win rate
55%
+ Follow
#2
Jonathan Wolleben
JMP Securities · Rank #38
Buy
$25.00+653.0% to target
Overall win rate
44%
+ Follow
#3
Judah Frommer
Morgan Stanley
Buy
$14.00+321.7% to target
Coverage
—
+ Follow
#4
Tara Bancroft
TD Cowen
Buy
No targeton KLRS
Coverage
—
+ Follow
#5
YZ
Yun Zhong
Wedbush
Buy
$17.00+412.0% to target
Coverage
—
+ Follow
KLRS stock forecast FAQ
What is KLRS's average 12-month price target?+
The 3 analysts with a live target average $18.67 for Kalaris Therapeutics, Inc. over the next 12 months, ranging from a $25.00 high to a $14.00 low.
Is KLRS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for KLRS?+
The Street-high target is $25.00 (Citizens), and the Street-low is $14.00 (Morgan Stanley). The average of all 3 active targets is $18.67.
How many Wall Street analysts cover KLRS?+
6 analysts have an active rating on Kalaris Therapeutics, Inc., and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering KLRS?+
Among analysts who currently cover KLRS, Daniil Gataulin of Chardan Capital has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $19.00 target.
What is Kalaris Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.52 per share (range $-0.58 – $-0.39) across 8 analysts. Full-year EPS is projected at $-2.03, rising to $-1.63 the following year.
How much revenue is Kalaris Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $11.4M next year.
Have analysts been upgrading or downgrading KLRS lately?+
As of Jul, 6 of 6 firms rate KLRS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KLRS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
